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Abstracts / Urological Science 27 (2016) S1eS23S22Purpose: Some studies reported a comparable oncological outcome and
better early continence rate of Retzius-preserving robotic assisted lapa-
roscopic radical prostatectomy (RALP). We want to compare the early
perioperative and continence outcome. And we are also eager to know if
the learning curve of Retzius-preserving surgery would compromise the
outcome or not?
Materials and Methods: We selected patient with organ-conﬁned
prostate cancer ( cT2c), PSA  40, Gleason score of biopsy  8, prostate
volume  50 ml and BMI < 35. We design a case control matching study
with 20 cases of each Retzius-preserving RALP and conventional RALP
group. Postoperative parameter and early continence result was
compared.
Results: From Febuary, 2015 to Febuary, 2016, total 84 cases of RALP were
performed in VGHTC. Twenty of them underwent Retzius-preserving
RALP. There is no statistical difference of preoperative characteristics.
There were no signiﬁcant differences in estimated blood loss, mean length
of hospital stay, intra- and postoperative complication rates, pathological
stage of disease, Gleason scores, tumour volumes and positive surgical
margins between the conventional RALP and Retzius-sparing RALP groups.
However, console time, Vesicourethral anastomosis time were longer for
Retzius-sparing RALP. There is no signiﬁcant difference of early continence
at 4 weeks between two groups.
Conclusion: Based on the early result of this study, Retzius-preserving
RALP is a feasible and safe treatment choice for localized prostate cancer.
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Purpose: Prostate cancer is a common cancer and it can often be treated
successfully. The 15-year survival rate is more than 90% in patients with
early stage, However, once the tumor metastasis occurred, the prognosis
got signiﬁcantly worse. Therefore, to identify patients with malignant
potential while diagnosing might improve clinical outcome. The aim of
this study was to evaluate the expression of SPOCK1 (sparc/osteonectin,
cwcv and kazal-like domains proteoglycan (testican) 1) and its clinical
signiﬁcance in prostate cancer.
Materials and Methods: SPOCK1 expression was measured by immuno-
histochemical staining of samples from 71 patients with prostate cancer.
The correlation between SPOCK1 expression and clinicopathological fea-
tures was quantitatively analyzed. The prognostic value of SPOCK1 for
overall survival was determined by Kaplan-Meier analysis and Cox pro-
portional hazard models. For underlying molecular mechanism, prostate
cancer cell lines were used and SPOCK1 expression was knock-down via
siRNA. Migration and invasion assay were performed to determined the
tumor malignancy. The downstream signaling pathway will be analyzed
with real-time RT-PCR and western blot.
Results: Seventy-one patients with mean age of 74.4 years (range 59 to 97
years) were included. Clinicopathological features, including histological
type, differentiation, lymph node metastasis, TNM stage, and tumor size
were assessed. Patients with high SPOCK1 expression were more prone to
be advanced stage. As to the prognosis, the median follow-up for overall
survival was 5.2± 2.9 years (range: 0.7 to 11.8 years). Moreover, a high
POCK1 expression level was correlated with poor survival. The underlying
mechanism is under investigation.
Conclusion: Our results suggest that SPOCK1 expression is enhanced in
prostate cancer. High SPOCK1 expression, either alone or in combinationwith other pathologic staging factors, may therefore serve as a poor
prognostic marker for prostate cancer.
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Purpose: Physicians ordering contrast imaging should identify patient
risks and prevent contrast-induced nephropathy (CIN). Our aim is to
determine whether patient-speciﬁc or non-patient-speciﬁc alerts in clin-
ical decision support system triggers higher compliance with guidelines to
prevent CIN.
Materials and Methods: A 3-arm cluster randomized controlled trial was
conducted in two university hospitals using the same computerized
physician order entry. Eligible physicians were randomized to receive
patient-speciﬁc alerts, non-patient-speciﬁc alerts or no intervention
(groups 1e3 respectively). Patient-speciﬁc alerts automatically prompted
only when CIN risk was encountered and provides patient-speciﬁc data to
physicians, while non-patient-speciﬁc alerts always prompted regardless
of risk without providing patient-speciﬁc data. CIN risk was stratiﬁed as
high-risk, low-risk and minimal-risk according to patient's renal function.
Contrast imaging order-cancellation rate was measured as primary
outcome.
Results: Orders for 5372 patients from 99 physicians were analyzed. Renal
function and risk distributions of patients were not statistically different
among groups. Order-cancellation rates were 32.1%, 14.3%, 1.7% for high
risk patients, and 7.2%, 3.0%, 1.3% for low risk patients in groups 1e3,
respectively. Using generalized linear model, signiﬁcant order-cancellation
factors in at-risk patients were non-patient-speciﬁc alert (p¼ 0.04), pa-
tient-speciﬁc alert (p< 0.0001), high CIN risk (p¼ 0.003), and physicians
with low contrast imaging ordering volume (p< 0.0001). Order-cancella-
tion effects were compared and measured by odds ratio (OR). For high risk
patients, patient-speciﬁc versus non-patient-speciﬁc alerts OR was sig-
niﬁcant at 2.73 (95%CI 1.09e6.84), while patient-speciﬁc vs. control
OR¼ 28.32 (95%CI 3.21e249.65), and non-patient-speciﬁc vs. control
OR¼ 9.17 (95%CI 0.96e87.55).
Conclusion: Patient-speciﬁc alert signiﬁcantly outperformed non-patient-
speciﬁc alert in physician compliance with guidelines.
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Purpose: To analyze the clinical outcome of patients with KC managed
with augmentation enterocystoplasty (AE).
Materials and Methods: We retrospectively collected and analyzed the
medical records and video-urodynamic (VUD) test results of 26 patients
who underwent AE as treatment for refractory KC during the period
2009e2014. Data from VUD studies performed before AE and 3e6 months
after surgery that were analyzed in this study included cystometric
bladder capacity (CBC), post-void residual (PVR) urine volume, maximum
urinary ﬂow rate (Qmax), voided volume and bladder compliance. A self-
report questionnaire was used to assess patient satisfaction with AE.
Results: Patients included 14women and 12men aged 20e43 years (mean
age, 28.5 years) with an average duration of ketamine abuse of 4.7 years
(range, 1e7 years). All patients had contracted bladder, 9 had hydro-
nephrosis and 10 had vesicoureteral reﬂux (VUR). There was signiﬁcant
improvement in CBC (52.7± 29.7 v 327± 69.4 mL, P< 0.0001), Qmax
(6.94± 4.32 v 13.7± 4.96 mL/s, P< 0.0001), PVR (8.08± 19.2 v
82.6± 91.5 mL, P< 0.0001), voided volume (44.1± 28.3 v 250.7 ± 133.4 mL,
